Zacks Investment Research lowered shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) from a hold rating to a sell rating in a research report released on Friday.

According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “

A number of other brokerages have also commented on VBLT. HC Wainwright set a $11.00 price target on shares of Vascular Biogenics and gave the company a buy rating in a research note on Tuesday, August 15th. ValuEngine upgraded shares of Vascular Biogenics from a sell rating to a hold rating in a research note on Thursday, August 17th. Finally, Chardan Capital boosted their price target on shares of Vascular Biogenics from $20.00 to $25.00 and gave the company a buy rating in a research note on Monday, November 6th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $16.00.

Shares of Vascular Biogenics (NASDAQ:VBLT) opened at $6.95 on Friday. Vascular Biogenics has a one year low of $3.90 and a one year high of $9.05.

An institutional investor recently bought a new position in Vascular Biogenics stock. KCG Holdings Inc. acquired a new position in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 45,106 shares of the biopharmaceutical company’s stock, valued at approximately $248,000. KCG Holdings Inc. owned about 0.17% of Vascular Biogenics at the end of the most recent reporting period. 7.26% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/vascular-biogenics-ltd-vblt-downgraded-by-zacks-investment-research/1730079.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.